USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
11 Jul 2022 | 02:45 PM GMT

Oncology Digital Health: Evidence Requirements from Payers and Regulatory Bodies

Anchored by:

Andrew Norden
Chief Medical Officer
ONCOHEALTH
Kevin Darcy
Director, Link Strategy
VEEVA

Participants:

Andrew Norden Chief Medical OfficerOncoHealth
Andrew Norden
Chief Medical OfficerOncoHealth
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Carole Tremonti VP Clinical Operations & StrategySimBioSys
Carole Tremonti
VP Clinical Operations & StrategySimBioSys
Gandolf Finke CEOSynagen
Gandolf Finke
CEOSynagen
Jeremy Sohn Jeremy Sohn Managing partnerP74 Ventures
Jeremy Sohn Jeremy Sohn
Managing partnerP74 Ventures
Jordi Ferrer Investment DirectorShip2B Ventures
Jordi Ferrer
Investment DirectorShip2B Ventures
Luis Fernandez Luque Chief Scientific OfficerAdhera Health
Luis Fernandez Luque
Chief Scientific OfficerAdhera Health
Seema Dadhania CRUK Convergence Science Clinical PhD FellowImperial College London
Seema Dadhania
CRUK Convergence Science Clinical PhD FellowImperial College London

About this Meeting

The marriage of digital health and oncology is very new, with companies still figuring out the best approach to establish in the market. For entrepreneurs, it is important to have as many options as possible, which makes clinical and economic evidence critical for most solutions to ease adoption. This requires a nuanced understanding of what the evidence standards are for different stakeholders. In this meeting, we will focus on payers and regulatory bodies.  

Join this session to break down the key questions:  

  • How can companies build an evidence base that is robust but also flexible enough to satisfy both payers and regulators in a cost effective manner?  
  • Working with payers has been an early area of opportunity within digital health and oncology, but many require clinical trials. Is this a good route for young companies?   
  • The nature of cancer treatment means that digital health is unlikely to treat the underlying issue. Digital products can play many roles within treatment - such as supporting mental health, comorbidities, etc - so how can companies build an evidence base that demonstrates both efficacy and value?  
  • What health economics results do digital health companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from digital health solutions in oncology?  
  • Due to the lack of industry-wide evidence frameworks for digital health, payers and regulators requirements are usually the same as drugs or medical devices. However, digital health solutions are very different in nature. How can the industry work together to evolve the evidence requirements from payers and regulatory bodies?